Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative intraperitoneal and systemic chemotherapy for Borrmann large type 3 and type 4 gastric cancer
ChiCTR2400083253Phase 2Not yet recruiting
- Sponsor
- Ruijin Hospital
- Start
- Apr 2024
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of paclitaxel, oxaliplatin and tegafur in gastric cancer (GC), sponsored by Ruijin Hospital. Primary endpoint: 3-year peritoneal recurrence rate. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
paclitaxeloxaliplatintegafur
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on ChiCTR2400083253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400083253.